Merck & Company, Inc. (MRK) Stake Increased by American Economic Planning Group Inc. ADV

American Economic Planning Group Inc. ADV lifted its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 0.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,579 shares of the company’s stock after buying an additional 4 shares during the quarter. American Economic Planning Group Inc. ADV’s holdings in Merck & were worth $486,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Vigilant Capital Management LLC lifted its position in shares of Merck & by 16.7% during the 1st quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after buying an additional 250 shares during the last quarter. Cascade Investment Advisors Inc. lifted its position in shares of Merck & by 15.5% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock worth $111,000 after buying an additional 232 shares during the last quarter. Harbour Capital Advisors LLC purchased a new stake in shares of Merck & during the 1st quarter worth approximately $127,000. Gradient Investments LLC lifted its position in shares of Merck & by 41.3% during the 1st quarter. Gradient Investments LLC now owns 2,306 shares of the company’s stock worth $147,000 after buying an additional 674 shares during the last quarter. Finally, Pinnacle Bank purchased a new stake in shares of Merck & during the 1st quarter worth approximately $152,000. Institutional investors and hedge funds own 73.02% of the company’s stock.

Several analysts have recently weighed in on MRK shares. Vetr upgraded shares of Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 price objective for the company in a research report on Monday, May 15th. Jefferies Group LLC restated a “sell” rating and set a $51.00 price objective on shares of Merck & in a research report on Wednesday, May 24th. Zacks Investment Research downgraded shares of Merck & from a “buy” rating to a “hold” rating in a research report on Thursday, May 25th. BMO Capital Markets restated a “buy” rating and set a $74.00 price objective on shares of Merck & in a research report on Tuesday, June 6th. Finally, Credit Suisse Group set a $72.00 price objective on shares of Merck & and gave the stock a “buy” rating in a research report on Tuesday, June 6th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $69.56.

TRADEMARK VIOLATION NOTICE: This news story was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.themarketsdaily.com/2017/09/11/merck-company-inc-mrk-stake-increased-by-american-economic-planning-group-inc-adv.html.

Merck & Company, Inc. (NYSE MRK) traded up 1.3450% during trading on Monday, hitting $65.1344. 5,604,123 shares of the stock were exchanged. The stock’s 50 day moving average is $62.98 and its 200-day moving average is $63.70. Merck & Company, Inc. has a one year low of $58.29 and a one year high of $66.80. The company has a market cap of $177.64 billion, a price-to-earnings ratio of 35.2650 and a beta of 0.81.

Merck & (NYSE:MRK) last announced its quarterly earnings data on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.14. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The firm had revenue of $9.93 billion during the quarter, compared to analyst estimates of $9.75 billion. During the same period last year, the company posted $0.93 EPS. The business’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities research analysts expect that Merck & Company, Inc. will post $3.87 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 6th. Shareholders of record on Friday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Thursday, September 14th. This represents a $1.88 dividend on an annualized basis and a yield of 2.93%. Merck &’s payout ratio is presently 76.11%.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply